Measures for Assessing Subjective Effects of Potential Reduced-Exposure Products

被引:17
作者
Hanson, Karen [1 ]
O'Connor, Richard [2 ]
Hatsukami, Dorothy [1 ]
机构
[1] Univ Minnesota, Tobacco Use Res Ctr, Minneapolis, MN 55414 USA
[2] Roswell Pk Canc Inst, Dept Hlth Behav, Buffalo, NY 14263 USA
关键词
NICOTINE REPLACEMENT THERAPY; BEHAVIORAL ECONOMIC-ANALYSIS; CARBON-MONOXIDE EXPOSURE; TRANSDERMAL NICOTINE; SMOKING-BEHAVIOR; CIGARETTE-SMOKING; DECREASES WITHDRAWAL; RANDOMIZED-TRIAL; ABUSE LIABILITY; TOXIN EXPOSURE;
D O I
10.1158/1055-9965.EPI-09-0971
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Potential reduced-exposure products (PREP) may reduce toxicant exposure and thereby may possibly reduce health risks associated with conventional tobacco use. However, lessened health risk to the individual or harm to the population through the use of PREPs is unknown. Research is being conducted to evaluate the possible health effects associated with PREP use. As part of this evaluation, it is critical to provide sound measures of subjective responses to PREPs to determine the use and the abuse potential of a product, that is, the likelihood that the product will lead to addiction. The goal of this paper is to conduct a systematic review of scales that have been used to measure the subjective responses to PREPs and examine their characteristics. In this article, scales are identified and the items on the scales are described. Scales are also examined to determine whether they are sensitive in testing PREPs. Furthermore, scales to assess PREPs are recommended to investigators. Where no scales exist, items that may be critical for the development and validation of new scales are identified. (Cancer Epidemiol Biomarkers Prev 2009;18(12):3209-24)
引用
收藏
页码:3209 / 3224
页数:16
相关论文
共 63 条
[1]   A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation [J].
Becker, Karen M. ;
Rose, Jed E. ;
Albino, Anthony P. .
NICOTINE & TOBACCO RESEARCH, 2008, 10 (07) :1139-1148
[2]   Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette [J].
Benowitz, Neal L. ;
Hall, Sharon M. ;
Stewart, Susan ;
Wilson, Margaret ;
Dempsey, Delia ;
Jacob, Peyton, III .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (11) :2479-2485
[3]   Nicotine intake and dose response when smoking reduced-nicotine content cigarettes [J].
Benowitz, Neal L. ;
Jacob, Peyton, III ;
Herrera, Brenda .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) :703-714
[4]   Nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokers [J].
Blank, Melissa D. ;
Sams, Cynthia ;
Weaver, Michael F. ;
Eissenberg, Thomas .
NICOTINE & TOBACCO RESEARCH, 2008, 10 (03) :417-421
[5]   Tobacco specific nitrosamines and potential reduced exposure products for smokers:: a preliminary evaluation of Advance™ [J].
Breland, AB ;
Acosta, MC ;
Eissenberg, T .
TOBACCO CONTROL, 2003, 12 (03) :317-321
[6]   Acute effects of Advance™:: a potential reduced exposure product for smokers [J].
Breland, AB ;
Evans, SE ;
Buchhalter, AR ;
Eissenberg, T .
TOBACCO CONTROL, 2002, 11 (04) :376-378
[7]   Clinical laboratory evaluation of potential reduced exposure products for smokers [J].
Breland, Alison B. ;
Kleykamp, Bethea A. ;
Eissenberg, Thomas .
NICOTINE & TOBACCO RESEARCH, 2006, 8 (06) :727-738
[8]  
Breland Alison B, 2002, Nicotine Tob Res, V4 Suppl 2, pS131
[9]  
Buchhalter A R, 2001, Nicotine Tob Res, V3, P111
[10]  
BUCHHALTER AR, 2009, NICOTINE TOB RES, V2, P39